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A Light in the Shadows of Carotid Artery StentingLong-awaited results from the CREST (Carotid Revasculari-
zation Endarterectomy versus Stenting Trial) study have
been recently presented1 and gave a new light on carotid
endarterectomy (CEA) and carotid stenting (CAS).
CREST compared CAS to CEA for the treatment of carotid
artery stenosis to prevent stroke in symptomatic and
asymptomatic patients. More than 2500 patients were
enrolled from more than 100 centers in North America and
Canada over a 9-year period. The occurrence of the
composite primary end-point of any stroke, myocardial
infarction, or death during the periprocedural period or
ipsilateral stroke on follow-up, was not significantly
different in CEA and CAS groups: stenting 7.2%, surgery
6.8%. The overall safety and efficacy of the two procedures
was largely the same with equal benefits for both men and
women, and for patients with and without previous
neurological symptoms. However, there were more heart
attacks (2.3%) in the surgical group compared to 1.1% in the
stenting group, and more strokes in the stenting group
(4.1%) versus 2.3% for the surgical group in the weeks
following the procedure. In particular, few strokes were
disabling; the rate of non-disabling stroke was 2.7% for CAS
vs. 1.4% for CEA, and the rate of disabling stroke was 1.4%
for CAS vs. 0.8% for CEA, without achieving statistical
significance.
With these new data from the CREST trial we can finally
re-evaluate the right place for CAS with respect to CEA.
CREST results highlight some important messages to a crit-
ical reader.
The first consideration is that CREST outcome rates are
the lowest yet reported in any randomized trial on CAS.
This can be explained since CREST was the only trial to
include asymptomatic and symptomatic patients and to
require only well-trained operators before randomization.
Besides the enrollment of low-risk population, there is no
doubt that the acceptable complication rates from CREST
are the consequences of significant advances in technology,
operators’ experience, and patient selection for stenting,
that have continued over the 8-year enrollment period.
Notably CREST was the only trial to have a lead-in phase to
train less experienced operators prior to the enrollment
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the findings of previous RCTs, which provided opposite and
negative figures for CAS. The three most recent trials, the
Endarterectomy Versus Angioplasty in Patients with Symp-
tomatic Severe Carotid Stenosis3 (EVA-3S) trial, the Stent-
Protected Angioplasty versus Carotid Endarterectomy4
(SPACE) trial, and the International Carotid Stenting
Study5 (ICSS) have indeed supported the notion that CEA is
safer than CAS. Since the appearance of these unfavorable
data for stenting, many of the original CAS enthusiasts have
expressed a note of caution6 and the need to select
patients more carefully. In the CREST study half of the
population was asymptomatic (47%, equally distributed in
CAS and CEA groups) justifying for an overall decreased
procedural risk compared to the other recent RCTs.
Nevertheless, even though detailed CREST data stratified
by symptoms are still unknown, CREST investigators
claimed that their risk rates were equally distributed
between CAS and CEA in both symptomatic and asymp-
tomatic patients.
The third message is that CREST results did not aim to
establish whether stenting or endarterectomy will win the
race, but more likely how these two procedures could be
selectively and properly applied to individual patients.
Depending on patient’s characteristics, one procedure
might have an advantage over the other. In an interaction
analysis, CREST found that stenting results were slightly
better for patients aged 69 and younger, with the benefit
increasing with decreasing age. Conversely, for patients
older than 70, surgical results were slightly superior to
stenting, with the benefits increasing along with the age.
This is the first example that stenting and endarterec-
tomy could both have their place as different treatment
options for carotid stenosis and could complement each
other, with positive or negative effects in certain patient
subgroups, which need to be further identified (i.e. vessel
morphology, gender, presence or absence of previous
symptoms, and time of onset of previous symptoms). In
recent years an increasing number of papers tried to define
risk scoring systems in order to improve CAS results
according to different patient populations.7,8d by Elsevier Ltd. All rights reserved.
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528 EditorialFinally, CREST results allowed experienced operators in
both techniques to adapt a treatment strategy tailored to
each patient. To this regard, only specialists who can offer
both options of treatment will offer the greatest benefit for
the patient.
Although CREST cannot solve all the issues raised by
other trials on CAS,9 and a number of ongoing RCTs are
awaited before a final decision, it is time to suggest that
both CAS and CEA could serve as valid treatment options
with similar safety in the treatment of carotid stenosis.
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